Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
More than 24 million Americans are infected with the human papillomavirus (HPV)(1), the virus that can cause one of the most common, yet least recognized, sexually transmitted diseases (STDs)...
3M announced today that Michael L. Eskew, 53, Chairman and CEO, UPS, has been elected to 3M's Board of Directors. Eskew has been appointed to serve on the Board's Audit and Public Issues...
3M announced today it has acquired GuardiaNet Systems Inc., a leading software company serving the public library market. Terms of the transaction were not disclosed. GuardiaNet's software and...
The United States Court of Appeals for the Third Circuit ruled against 3M yesterday in a federal antitrust claim brought in 1997 by LePage's Inc., a transparent tape competitor of 3M. 3M intends...
3M Health Care now offers the only surgical clipper on the market with a fixed disposable blade assembly that can be operated by either rechargeable battery or electrical cord. The company will...
"Electrical Performance Advantages of Ultrathin Dielectric Materials Used for Power-Ground Cores in High-Speed, Multilayer Printed Circuit Boards" will be presented at IPC Printed Circuits Expo...
3M today announced positive clinical results in pivotal Phase III studies of Aldara (imiquimod) Cream, 5%, an immune response modifier (IRM), for multiple actinic keratoses (AK) and superficial...
3M Automotive Division's 3M solar reflecting film was named one of the winners of the 2003 PACE Award. The announcement was made last night (March 2) during a banquet at the Detroit Opera House....
3M Health Information Systems Division and Premier Inc. today announced a strategic agreement to market 3M's DRG Assurance consulting, assessment and documentation improvement services in...
Following today's joint announcement by Eli Lilly and Company and 3M to suspend clinical trials of resiquimod, an investigational Immune Response Modifier (IRM) compound for the treatment of...
These contacts are intended only for the media. If you are not a member of the media, please call 1-888-3M HELPS (1-888-364-3577).
We will get back to you within one business day.
Subscribe to receive automatic updates via email for 3M news & stories.